PGI(2) receptor agonist demonstrates efficacy in pulmonary arterial hypertension.
The first orally active nonprostanoid PGI(2) receptor agonist has shown highly positive results in a Phase IIa study for the treatment of pulmonary arterial hypertension.
Ward
Ian
I
D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D044006:Receptors, Epoprostenol / Q000819:agonists*
D044006:Receptors, Epoprostenol